94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1587126
AMY-101 as Complement C3 Inhibitor for Periodontitis Therapy: Mechanisms, Efficacy, and Clinical Translation
Provisionally accepted- 1China Medical University, Shenyang, China
- 2Shenyang Medical College, Shenyang, Liaoning Province, China
- 3Cardiff University, Cardiff, United Kingdom
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Periodontitis is a chronic inflammatory disease characterized by gingival inflammation, alveolar bone resorption, and periodontal tissue destruction. Complement activation, particularly through the C3 component, plays a critical role in the inflammatory processes underlying periodontitis. AMY-101, a selective inhibitor of complement C3, has demonstrated significant potential in modulating complement activity and mitigating periodontal inflammation. This study comprehensively evaluates AMY-101's effects through in vitro, preclinical, and clinical studies.Mechanistic investigations revealed that AMY-101 effectively suppresses pro-inflammatory cytokines and matrix metalloproteinases (MMPs), reducing tissue destruction. Preclinical models confirmed AMY-101's ability to improve clinical parameters such as probing pocket depth, attachment loss, and bone preservation. Moreover, clinical trials demonstrated AMY-101's safety and efficacy in reducing gingival inflammation and bleeding without serious adverse events. These findings highlight AMY-101's therapeutic potential for periodontitis and broader applicability in other complement-driven inflammatory diseases.
Keywords: AMY-101, Periodontitis, complement system, Complement C3, Bone Resorption, Bone formation
Received: 04 Mar 2025; Accepted: 08 Apr 2025.
Copyright: © 2025 Li, Xu, Ayre and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wayne Nishio Ayre, Cardiff University, Cardiff, CF10 3AT, United Kingdom
Xiaohan Liu, China Medical University, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.